Novo Nordisk Hit With Suit for Underwhelming CagriSema Trial (1)
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
Ozempic maker Novo Nordisk failed to disclose more payments made to healthcare groups - watchdog
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...
Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline - NVO
NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
FiercePharma11h
Moderna, Novo Nordisk slammed for breaching UK drug marketing code yet again
Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk reports topline data from Phase Ib/IIa trial of weight loss therapy
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week’s news.